(Q34695715)

4 August 2017

1 reference

title

Androgen replacement therapy and prostate safety (English)

1 reference

4 August 2017

Alvaro Morales

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

41

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

113-120

1 reference

Endocrine dysfunction in impotence: incidence, significance and cost-effective screening.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Practical consequences of the validation of a mathematical model in assessment of partial androgen deficiency in the aging male using bioavailable testosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

A critical evaluation of simple methods for the estimation of free testosterone in serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Androgens in men--uses and abuses

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

The use and misuse of androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Androgen and progestagen effects on plasma lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Androgens and the risk of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Obstructive sleep apnea syndrome induced by testosterone administration

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Regulation of prostate growth

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Prospective study of sex hormone levels and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Hormonal predictors of prostate cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Do diet and androgens alter prostate cancer risk via a common etiologic pathway?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Longitudinal evaluation of serum androgen levels in men with and without prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Carcinoma of the prostate: relationship of pretreatment hormone levels to survival

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Response of men with advanced prostatic carcinoma to exogenous administration of testosterone.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Endocrine patterns in patients with benign and malignant prostatic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Use of DHEA in a patient with advanced prostate cancer: a case report and review

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2801%2900039-2

7 January 2021

10.1016/S0302-2838(01)00039-2

Identifiers

DOI

1 reference

4 August 2017

1 reference